The Phosphotyrosine Binding-like Domain of Talin Activates
Integrins*
David A.
Calderwood
,
Boxu
Yan
,
Jose M.
de Pereda§,
Begoña García
Alvarez§,
Yosuke
Fujioka
,
Robert C.
Liddington§, and
Mark H.
Ginsberg
¶
From the
Division of Vascular Biology, Department of
Cell Biology, The Scripps Research Institute and the
§ Program on Cell Adhesion, The Burnham Institute,
La Jolla, California 92037
Received for publication, December 17, 2001, and in revised form, March 4, 2002
 |
ABSTRACT |
Cellular regulation of the ligand binding
affinity of integrin adhesion receptors (integrin activation) depends
on the integrin
cytoplasmic domains (tails). The head domain of
talin binds to several integrin
tails and activates integrins. This
head domain contains a predicted FERM domain composed of three
subdomains (F1, F2, and F3). An integrin-activating talin fragment was
predicted to contain the F2 and F3 subdomains. Both isolated subdomains bound specifically to the integrin
3 tail.
However, talin F3 bound the
3 tail with a 4-fold higher
affinity than talin F2. Furthermore, expression of talin F3 (but not
F2) in cells led to activation of integrin
IIb
3. A molecular model of talin F3 indicated that it resembles a phosphotyrosine-binding (PTB) domain. PTB
domains recognize peptide ligands containing
turns, often formed by
NPXY motifs. NPX(Y/F) motifs are highly
conserved in integrin
tails, and mutations that disrupt this motif
interfere with both integrin activation and talin binding. Thus,
integrin binding to talin resembles the interactions of PTB domains
with peptide ligands. These resemblances suggest that the activation of
integrins requires the presence of a
turn at NPX(Y/F)
motifs conserved in integrin
cytoplasmic domains.
 |
INTRODUCTION |
Integrin adhesion receptors are essential for the development and
survival of multicellular animals. Normal functioning of the >20 human
integrins often requires dynamic cellular regulation of integrin ligand
binding affinity (integrin activation). Activation of integrins is
important in many biological processes, including cell migration,
hemostasis, extracellular matrix assembly, tumor metastasis, and the
immune response (1, 2). Integrin 
heterodimers generally possess
two short cytoplasmic domains (tails). The integrin
tail plays a
central role in the activation process, probably by undergoing
regulated interactions with certain cytoplasmic proteins (1, 3).
Talin is an abundant and widely expressed 250-kDa integrin
tail-binding protein implicated in integrin activation (4). Talin is
composed of a 50-kDa head and 205-kDa rod domain. The head domain
contains a major integrin-binding site (5-7), and expression of a
1071-residue fragment of talin containing the head domain in cells
leads to activation of integrin
IIb
3 (5). The capacity of this fragment to activate integrin
IIb
3 is lost when the head domain is
deleted from it or when the
3 cytoplasmic domain is
truncated (5). Talin binding to integrin
tails can be regulated via
calpain proteolysis (6) or through the binding of phosphoinositides
(8). Furthermore, the phosphorylation of either talin and/or integrin
(9, 10) could provide additional mechanisms for regulation of
integrin-talin interactions. Thus, the talin head domain is implicated
in integrin activation, and modulation of its binding to integrins is
likely to contribute to the regulation of integrin activation.
The talin head domain contains a predicted FERM domain (band
four-point-one/ezrin/radixin/moesin
homology domain) (11). FERM domains are found in a number of proteins
and often mediate their interactions with the cytoplasmic domain of
transmembrane proteins (12, 13). The crystal structures of the FERM
domains from moesin, radixin, and band 4.1 (14-17) reveal a very
similar overall fold. The FERM domain consists of a trefoil arrangement of three subdomains, each showing similarity to known domains. The
first subdomain, F1 (using the nomenclature of Pearson et al. (17)), contains a five-stranded
sheet with an
helix running across it and is similar to ubiquitin. The F2 subdomain is
entirely
helical with a short linker region and shows similarity to
the acyl-CoA-binding protein. The F3 subdomain is a sandwich of two
orthogonal antiparallel
sheets followed by an
helix; this fold
is found in a number of structures, including the
phosphotyrosine-binding (PTB)1 and pleckstrin
homology domains. In this study, we have localized a principal integrin
tail-binding site of talin to the predicted 96-residue PTB-like
subdomain within the talin FERM domain and shown that expression of
this PTB-like F3 subdomain leads to integrin activation. Furthermore,
like other PTB domain ligands, the capacity of the
3
tail to bind the talin PTB-like domain depends on the integrity of a
turn-forming NPXY motif. These similarities between integrin binding to talin and PTB domain-ligand interactions suggest that activation of integrins by the talin PTB-like F3 subdomain requires a stable
turn at NPX(Y/F) motifs conserved in
many integrin
cytoplasmic domains.
 |
EXPERIMENTAL PROCEDURES |
Antibodies and cDNAs--
Anti-talin (8d4; Sigma),
anti-hemagglutinin (12CA5; American Type Culture Collection), anti-Tac
(7G7B6; American Type Culture Collection), anti-Syk (4D10; Santa Cruz
Biotechnology), anti-Myc (Santa Cruz Biotechnology), and anti-GST (B14;
Santa Cruz Biotechnology) monoclonal antibodies and anti-Dok polyclonal
antibody (Santa Cruz Biotechnology) were obtained commercially. The
anti-
IIb
3 monoclonal antibodies PAC1 and
anti-LIBS6 and the
IIb
3-specific antagonist Ro43-5054 have been described previously (3). cDNAs encoding Tac-
5, chicken talin-(186-435), mouse talin-(1-1071), mouse talin-(434-1071) (residue numbers refer to the sequences in
Swiss Protein Database entry TALI_MOUSE (accession number P26039)), human Syk, Syk-(1-330) (entry KSYK_HUMAN (accession number
P43405)), mouse Numb (entry NUMB_MOUSE (accession number
Q9QZS3)), mouse Dok (entry TrEMBL (accession number P97465)), and
IIb,
3, and
3(Y747A) human
integrin tail model proteins have been described previously (5,
18-22). cDNAs encoding mouse talin-(186-434), talin-(206-305)
(F2), and talin-(309-405) (F3) were amplified by PCR and subcloned
into the bacterial expression vector pGEX or the mammalian expression
vector pcDNA3.1. The 5'-primer was designed to allow introduction
of an N-terminal hemagglutinin tag during expression in mammalian
cells. A cDNA for the mouse Dok PTB domain (amino acids 149-256;
entry TrEMBL (accession number P97465)) was amplified by PCR and cloned
into pCMV-Tag3 (Stratagene) to allow expression of an N-terminally
c-Myc-tagged protein.
Purification of Recombinant Proteins--
Recombinant model
proteins of integrin cytoplasmic tails and GST fusion proteins were
expressed and purified as previously described (5, 19). Electrospray
ionization mass spectroscopy revealed that integrin tail model proteins
varied by <0.1% from the predicted molecular mass for the
non-phosphorylated proteins (19). For surface plasmon resonance (SPR)
experiments, GST was removed by addition of thrombin (~1 unit/mg of
protein) and mixing overnight at room temperature.
p-Aminobenzamidine beads (Sigma) and glutathione-Sepharose
4B beads (Amersham Biosciences) were then added to the mixture to
remove the thrombin and GST. Proteins were dialyzed in running buffer
(75 mM NaCl, 1.3 mM
Na2HPO4, and 2.2 mM
NaH2PO4, pH 7.4).
Affinity Chromatography with Recombinant Integrin
Tails--
Affinity chromatography was performed using recombinant
integrin tails bound to His-Bind resin (Novagen) as previously
described (5, 6, 19). 5 µl of coated beads and 1 µg of purified GST
fusion protein were routinely used. Bound proteins were fractionated by
SDS-PAGE and analyzed by Western blotting.
SPR--
SPR analysis was performed as previously described
using a BIAcore 3000 instrument (6). Briefly, sufficient streptavidin to generate an increase of ~500 resonance units was coupled to activated CM5 sensor chips (6). Recombinant
3 tails were
biotinylated on a unique cysteine residue and immobilized on sensor
chips via a biotin-avidin linkage (6). Tails were immobilized at a
level previously determined to minimize mass transport artifacts. The binding of a range of concentrations of purified recombinant talin subdomains to the
3-coated chip was then analyzed.
Analyte was injected using the KINJECT command specifying a 90 s
association phase and a 40 s dissociation phase. Following completion
of KINJECT, dissociation was followed for at least another 60 s.
The use of KINJECT delays removal of the injection needle and so
minimizes instrument noise at the start of the dissociation phase;
however, a change in resonance units can be detected when the needle is removed following completion of the KINJECT dissociation phase 130 s after the start of the injection. The chip surfaces were regenerated
with 2 M NaCl between experiments. All parameters were
measured at a flow rate of 20 µl/min in running buffer.
Data Analysis--
Sensorgrams were analyzed, and rate constants
were calculated as previously described (6). The kinetic data were
interpreted in the context of a first-order kinetic model: A + B = AB (23-25). For such a model, the association
(kon) and dissociation
(koff) rate constants are described by Equation 1.
|
(Eq. 1)
|
Equation 1 can be expressed with the parameters used in SPR
analysis as follows (Equation 2),
|
(Eq. 2)
|
where R is the response in resonance units at time
t, Rmax is the maximum response at
saturating concentrations of analyte, and C is the
concentration of the analyte solution. Hence, the gradient of the
dR/dt versus R plot,
ks, is described by Equation 3.
|
(Eq. 3)
|
The dissociation rate constant value obtained from Equation 3
may not be reliable for low ranges (26); therefore,
koff values were calculated from the
dissociation phases of the sensorgrams using Equation 4,
|
(Eq. 4)
|
where R0 represents the response in
resonance units at the start of dissociation,
t0. The apparent equilibrium dissociation constant, Kd, was then determined from the ratio of
these two kinetic constants
(koff/kon).
Kd was also calculated from Scatchard analysis of
equilibrium binding using Equation 5,
|
(Eq. 5)
|
where Req is the response in resonance
units at equilibrium.
FACS Analysis of the Activation State of
IIb
3--
Chinese hamster ovary (CHO)
cells expressing integrin
IIb
3 (3) were
transiently transfected with cDNAs encoding Tac-
5 (1 µg) and
talin fragments (3 µg) using LipofectAMINE Plus (Invitrogen). 24 h later, three-color flow cytometry was performed as described previously (3, 5). Briefly, cells were suspended and stained with PAC1
and then washed and stained with biotinylated anti-Tac monoclonal
antibody 7G7B6. Bound PAC1 and 7G7B6 were detected with fluorescein
isothiocyanate-conjugated goat anti-mouse IgM (BioSource,
International) and streptavidin-conjugated R-phycoerythrin (Molecular
Probes, Inc.), respectively. 5 min prior to analysis, propidium iodide
(2 µg/ml final concentration) was added. Cells were washed and
analyzed on a FACSCalibur instrument (BD PharMingen). PAC1 binding to
live (propidium iodide-negative) transfected (7G7B6-positive) cells was
assessed.
IIb
3 activation was quantified
as an activation index defined as (F
F0)/(Fmax
F0), where F is the median
fluorescence intensity of PAC1 binding, F0 is
the median fluorescence intensity of PAC1 binding in the presence of
the
IIb
3 antagonist Ro43-5054 (1 µM), and Fmax is the median
fluorescence intensity of PAC1 binding in the presence of the
IIb
3-activating monoclonal antibody anti-LIBS6 (2 µM). The percentage change in activation
index (AI) following transfection was calculated as 100 × (AI
AI0)/(AI0), where AI0 = AI in cells transfected with the control vector.
Modeling of the Talin PTB-like Subdomain--
Three-dimensional
homology models of the F3 subdomain of talin were made
using the program Modeler 4 (27). Initial sequence alignments made
with ClustalW (28) were manually edited to match the hydrophobic
residues that constitute the core of the subdomain limiting the
presence of insertions to the loops. The crystal structures of moesin,
radixin, and band 4.1 (14-17) were used as templates independently or
combined. The quality of the models was assessed with the program WHAT
IF (29).
 |
RESULTS |
A 250-Amino Acid Fragment of the Talin Head Domain
(Talin-(186-435)) Binds the
3 Tail and Activates
Integrin
IIb
3--
A talin fragment that
contains the head domain (talin-(1-1071)), but not one that lacks the
head domain (talin-(434-1071)), can activate
IIb
3 integrins (5). To determine whether
a portion of the talin head domain was sufficient for these functions,
we analyzed a fragment of the talin head containing
Glu186-Gln435 that binds to the integrin
1D tail (5). Talin-(186-435) bound to the
3 (but not
IIb) tail (Fig.
1A), and binding was inhibited by a Tyr-to-Ala mutation in the first NPXY motif,
3(Y747A) (Fig. 1A). This integrin-binding
fragment of the head domain was sufficient to activate
IIb
3 integrins in CHO cells (Fig.
1B). The magnitude of activation was comparable to that
observed for the previously described talin-(1-1071) fragment (5)
(mean increase in activation index = 76% (p = 0.001) versus 65% (p = 0.0003)).
Furthermore, a fragment of talin that lacks this region
(talin-(434-1071)) had no effect on the activation state of
IIb
3 (mean change in activation
index = 3%, p > 0.7) (Fig. 1B). The
expression of talin-(186-435), talin-(1-1071), and talin-(434-1071)
was confirmed in immunoblots of the transfected cells (data not shown).
Thus, expression of a 250-amino acid
3 tail-binding
fragment of the talin head domain is sufficient to induce
IIb
3 activation.

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 1.
Talin-(186-435) binds to
3 tails and activates integrin
IIb 3.
A, purified recombinant GST-talin-(186-435) was mixed with
beads coated with recombinant 3 (lane 1),
3(Y747A) (lane 2), or IIb
(lane 3) cytoplasmic tails. Bound proteins were fractionated
by SDS-PAGE, and GST-talin-(186-435) was detected by Western blotting
with anti-GST antibodies. Loading of the recombinant integrin tails
onto the beads was assessed by Coomassie Blue staining. Molecular mass
markers (in kilodaltons) are indicated. B, CHO cells
expressing IIb 3 were transfected with
cDNA encoding talin-(186-435), talin-(1-1071), talin-(434-1071),
or empty vector (3 µg) along with Tac- 5 (1 µg) as a transfection
marker. Cells were then harvested and analyzed by flow cytometry.
Binding of the activation-specific
anti- IIb 3 monoclonal antibody PAC1 to
transfected cells (stained with anti-Tac antibody 7G7B6) was measured,
and activation indices were calculated. Results represent mean increase
in activation index ± S.E. (n = 6). *,
p < 0.001 (Student's t test).
|
|
The Integrin-binding Fragment of the Talin Head Domain Contains the
F2 and F3 Subdomains of the Predicted Talin FERM Domain--
As
described above, we have localized an integrin-binding and -activating
fragment of the talin head to residues 186-435. This fragment contains
part of a predicted FERM domain (11). FERM domains are found in a large
number of proteins; however, the overall sequence identity is often low
(12, 13). BLAST analysis of the talin head domain revealed highly
significant similarity to consensus FERM domain sequences
(Conserved Domain Database sequences CD:pfam00373 and CD:smart-00295)
generated using the Pfam and SMART programs (score 243, E = 2 × 10
65; and score 153, E = 2 × 10
38 , respectively).
Individual BLAST comparison of the talin head domain with the sequences
of crystallized moesin, radixin, and band 4.1 FERM domains demonstrated
25, 25, and 20% identities and 46, 47, and 37% similarities,
respectively. These similarities establish significant
(E = 4 × 10
10, 4 × 10
10, and 3 × 10
6, respectively)
homology of this region of talin to these FERM domains. FERM domains
are composed of three subdomains (F1, F2, and F3) (14-17). To identify
the boundaries of the subdomains within the talin FERM domain, we
aligned the talin head domain sequence with other FERM domains (Fig.
2). Superposition of the moesin secondary
and tertiary structural elements (17) allowed us to predict that the
mouse talin F2 subdomain extends from Ser206 to
Leu305 and the F3 subdomain from Gly309 to
Ser405 (numbered according to Swiss Protein Database entry
TALI_MOUSE (accession number P26039)). Superposition of the moesin
structure on multiple alignments of FERM domains generated by ClustalW
(16) and hydrophobic cluster (12) analyses predicted very similar domain boundaries for the talin F2 and F3 subdomains. Therefore, three
sequence alignments predicted identical boundaries for the talin F2 and
F3 subdomains and indicated that talin-(186-435) contains all of the
F2 and F3 subdomains, but only the last predicted
strand of the F1
subdomain. This suggested that the F2 and/or F3 subdomain might be
responsible for
tail binding and integrin activation.

View larger version (108K):
[in this window]
[in a new window]
|
Fig. 2.
Sequence alignment of FERM domains.
The primary sequences of eight FERM domain-containing proteins
were aligned using the MultAlign program (46). Highly conserved
(>90%) residues are shown in red, and less conserved
(>50%) residues are shown in blue. Consensus symbols are
as follows: ! is anyone of IV, % is anyone of FY, and # is
anyone of NDQEBZ. The secondary structural elements of moesin (17) are
indicated above the alignment (bars represent helices, and
arrows represent strands), and their localization within
the F1 (purple), F2 (green), and F3
(orange) subdomains is color-coded. The start positions of
talin fragments (residues 185, 206, and 309) are marked. The six highly
conserved buried core FERM residues identified by Pearson et
al. (17) are indicated (*).
|
|
The Isolated Talin F3 Subdomain Binds the
3
Cytoplasmic Tail with High Affinity--
As described above, a talin
fragment containing both predicted F2 and F3 subdomains bound integrin
cytoplasmic domains. We therefore prepared individual F2
(talin-(206-305)) and F3 (talin-(309-405)) subdomains.
Affinity chromatography revealed that both F2 and F3 subdomains bound
the
3 tail (Fig.
3A). As observed for larger talin fragments, both F2 and F3 exhibited greatly reduced binding to
the
3(Y747A) tail and almost undetectable binding to the
IIb tail (Fig. 3A). Both talin F2 and F3
subdomains also bound to the
1A and
1D
integrin cytoplasmic tails, and binding was reduced by Tyr-to-Ala
mutations in the first NPXY motif of these tails (data not
shown). The binding was not due to a nonspecific interaction with the
tail, as purified GST did not bind (data not shown). Furthermore,
removal of the GST moiety by thrombin digestion did not impair the
ability of either the F2 or F3 subdomain to bind to
3
tails (see below). Thus, both predicted F2 and F3 subdomains of the
talin FERM domain bound specifically to the
3 tail.

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 3.
Talin F2 and F3 subdomains bind integrin
tails. A, beads coated with
recombinant 3, 3(Y747A), or
IIb tail model proteins were incubated overnight with 1 µg of recombinant GST-talin F2 or F3. Bound proteins were
fractionated by SDS-PAGE, and recombinant talin proteins were detected
by Western blotting with anti-GST antibodies. Loading of the model
proteins onto the beads was assessed by Coomassie Blue staining.
Starting material represents 5% of the input material.
B, the binding of talin subdomains to 3 tails
was analyzed by SPR. Sensorgrams of the association and dissociation
phases for talin F2 and F3 binding to 3 tails are shown.
Talin subdomains at 50, 75, 125 and 200 nM were
injected over a surface coated with ~480 resonance units
(RU) of biotin-maleimide-modified 3 tail for
90 s at a flow rate of 20 µl/min. Similar results were obtained
in three independent experiments.
|
|
We examined the real-time binding of each of these subdomains to the
3 tail by SPR. SPR analysis was performed using
biotinylated
3 tail model proteins immobilized on a
streptavidin-coated sensor chip (coupling level of 500 resonance
units), and the data were analyzed in the context of a first-order
kinetic model (A + B = AB) (6). These analyses revealed typical
association and dissociation phases for both talin F2 and F3 subdomains
(Fig. 3B). Under similar conditions, no binding of
talin-(1-280) or talin-(1-186) was detected, consistent with their
lack of interaction in affinity chromatography experiments (5) (data
not shown). Furthermore, as previously observed for the talin head
domain (6), neither the talin F2 nor F3 subdomain bound to
streptavidin-coated chips lacking immobilized
3 ligand
(data not shown). Data were analyzed using Equations 1-5, defined
under "Experimental Procedures." The association rate constant
kon was obtained from Equation 3 (Fig.
4B) using the association
phase of the curve, and the dissociation rate constant
koff was obtained from the dissociation phases
of the sensorgrams using Equation 4 (23, 25). Using this method, rather
than BIAevaluation software, the r2 values
reported in Fig. 4 provide a measure of the goodness of fit (25). As
recommended by the manufacturer (BIAcore, Uppsala, Sweden), data
collected 10 s after injection start or stop were excluded from
the analysis to avoid sample dispersion effects. At the ligand coupling
level used, koff values (calculated from Equation 4) were independent of the concentration of analyte (talin F2
or F3 subdomain) used (Fig. 4A). This indicates negligible rebinding of analyte during the dissociation phase. Plots of
ks versus analyte concentration (Fig.
4B) were also linear. This is consistent with a simple
first-order interaction and facilitates calculation of
kon from Equation 3. These analyses allowed us to calculate that talin F3 bound the
3 tail with a
4-fold higher affinity than talin F2 (Kd = 130 ± 10 and 540 ± 40 nM, respectively), primarily due
to a markedly reduced on-rate for talin F2 ((3.9 ± 0.2) × 103 M
1 s
1) relative
to F3 ((3.3 ± 0.1) × 104
M
1 s
1) (Table
I). The dissociation constants
(Kd) calculated using kinetic parameters are in good
agreement with those calculated from equilibrium binding Scatchard
plots using Equation 5 (Fig. 4C and Table I) and support a
simple first-order interaction. The presence of the F2 subdomain does
not notably enhance or inhibit talin binding to integrin
tails, as
constructs containing the F2 and F3 subdomains retain the ability to
bind
tails (Fig. 1A), and the isolated talin F3
subdomain binds the
3 tail with an affinity
(Kd = 130 ± 10 nM) that is similar
to that of the intact (F2 and F3 subdomain-containing) talin head
domain (Kd = 91 nM) (6). Although the
talin rod domain contains additional integrin
tail-binding sites
(5, 30), the head domain binds with a 37-fold higher affinity than the
rod domain (6), and the F3 subdomain binds with an affinity similar to that of the intact head domain. Therefore, the talin F3 subdomain contains a major integrin
tail-binding site.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 4.
Estimation of parameters for talin F2 and F3
binding to 3 tails.
A, values of the dissociation rate constant
koff calculated using Equation 4 are plotted
against the concentrations of talin subdomains injected. Note that
koff is independent of subdomain concentration.
B, ks is plotted versus the
concentration of talin subdomains injected. The slope of the line
obtained by linear regression provides the estimate of the association
rate constant kon (Equation 3). C,
shown are the results from Scatchard analysis of equilibrium binding.
The fitted values for the response at equilibrium
(Req) are plotted versus the ratio
Req/C. The slope of the line,
estimated by linear regression, is equal to 1/Kd
(Equation 5). RU, resonance units.
|
|
View this table:
[in this window]
[in a new window]
|
Table I
Kinetics of the binding of the talin F2 and F3 subdomains to integrin
3 tails
Talin F2 and F3 binding to 3 tails was measured by SPR, and
the association (kon) and dissociation
(koff) rates were calculated using Equations 1-4.
The apparent equilibrium dissociation constant Kd
was then determined from the ratio of these two kinetic constants
(koff/kon) or from Scatchard
analysis of equilibrium binding using Equation 5. Kinetic constants
represent mean ± S.D.
|
|
The Talin F3 Subdomain Activates Integrins--
As described
above, we narrowed an integrin-binding and -activating site in the
talin head to a fragment containing the F2 and F3 subdomains and found
that both subdomains can bind to the
3 tail. We
therefore tested the ability of each subdomain to activate this
integrin. To do this, we transfected
IIb
3-expressing CHO cells with cDNAs
encoding hemagglutinin-tagged talin F2 or F3 and measured binding of
the activation-specific antibody PAC1 by flow cytometry. Cells
transfected with talin F3 (as identified by surface expression of
cotransfected Tac-
5) exhibited increased PAC1 binding, resulting in
a rightward tilt of the contour plot (Fig.
5A). A similar effect was
observed for cells transfected with talin-(1-1071) (Fig.
5A). However, cells expressing talin F2 displayed a contour
plot similar to that of cells transfected with empty vector or the
non-activating talin-(434-1071) fragment (Fig. 5A). In all
cases, the increased PAC1 binding could be completely inhibited by the
IIb
3 antagonist Ro43-5054 (Fig.
5A and Table II). Calculation
of the activation index of transfected cells indicated that expression
of talin F3 resulted in
IIb
3 activation (Fig. 5B). However, transfection of talin F2 resulted in
PAC1 binding similar to that observed in cells transfected with empty vector or the non-activating talin-(434-1071) fragment (Fig.
5B and Table II). In all cases, the talin fragments were
well expressed (Fig. 5C).

View larger version (45K):
[in this window]
[in a new window]
|
Fig. 5.
Expression of the talin F3 subdomain leads to
activation of
IIb 3.
CHO cells expressing IIb 3 were
transiently transfected with cDNA (1 µg) encoding Tac- 5 along
with cDNA (3 µg) encoding talin F2 or F3, talin-(1-1071),
talin-(434-1071), or empty vector. The binding of PAC1
(activation-specific anti- IIb 3 monoclonal
antibody) and 7G7B6 (to identify transfected cells) was then assessed
by FACS analysis. A, shown are contour plots of cells stably
expressing IIb 3 transfected with the
indicated cDNAs in the absence or presence of the
IIb 3 antagonist Ro43-5054. B,
the activation indices of transfected cells were calculated as
described under "Experimental Procedures," and the percentage
change from cells transfected with empty vector is plotted (mean ± S.E., n = 9). *, p < 0.005 (Student's t test). C, the expression of
recombinant talin subdomains in transfected CHO cells was examined by
immunoblotting of SDS-PAGE-fractionated cell lysates (7 µg).
HA, hemagglutinin.
|
|
View this table:
[in this window]
[in a new window]
|
Table II
Integrin activation by talin fragments
The geometric mean fluorescence intensity (MFI) of PAC1 binding to CHO
cells expressing IIb 3 or
IIb 3(Y747A) transfected with talin fragments or
empty vector (3 µg) was measured by FACS analysis in the presence or
absence of the IIb 3 antagonist Ro43-5054.
Activation indices were calculated as described under "Experimental
Procedures," and the percentage change from cells transfected with
control vector was calculated. Results are expressed as mean ± S.E.
|
|
Mutations in an NPX(Y/F) motif that is conserved in most
integrin
tails (31) inhibit integrin activation (3, 32). Such a
mutation (
3(Y747A)) inhibited the binding of talin F3 (Fig. 3A) to integrin
tails and also inhibits the
binding of intact talin (5). We therefore assessed the effect of this mutation on the capacity of talin F3 to activate integrin
IIb
3. Integrin
IIb
3 containing this mutation
(
IIb
3(Y747A)) was not activated by
expression of talin F3 (Fig. 6 and Table
II), although PAC1 binding could be induced by addition of the
activating antibody anti-LIBS6 (Fig. 6A). Therefore,
expression of the 96-amino acid F3 subdomain of talin (but not the F2
subdomain) activates integrin
IIb
3, and
this activation is inhibited by a mutation that disrupts the
NPXY motif in the
3 cytoplasmic tail.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 6.
Mutation of the
3 NPXY
motif blocks
IIb 3
activation. CHO cells expressing
IIb 3(Y747A) were transiently transfected
with cDNA (1 µg) encoding Tac- 5 along with cDNA (3 µg)
encoding talin F2 or F3 or empty vector and analyzed as described in
the legend to Fig. 5. A, shown are contour plots of cells
transfected with the indicated cDNAs in the presence or absence of
the IIb 3-activating antibody anti-LIBS6.
B, the activation indices of transfected cells were
calculated, and the percentage change from cells transfected with empty
vector is plotted (mean ± S.E., n = 6).
C, the expression of recombinant talin subdomains in
transfected CHO cells was examined by immunoblotting of
SDS-PAGE-fractionated cell lysates (7 µg). HA,
hemagglutinin.
|
|
Talin F3 Is a PTB-like Domain--
The sequence similarity of
talin to FERM proteins of known structure (see above) is sufficient to
build a reliable three-dimensional homology model of the F3 subdomain
of talin. The best model, as judged by the program WHAT IF (29), was
obtained using the crystal structure of moesin (15, 17) as template
(Fig. 7). The model has good structure
packing quality (Z-score of
2.34) and distribution of
hydrophobic residues to the interior/hydrophilic groups to the
exterior of the folded domain (root mean square
Z-score of 0.96), indicating that the PTB fold is compatible
with the sequence of the F3 subdomain of talin. In the predicted
structure, Val315, Leu330, Ile332,
Val337, Val340, Ile348,
Trp351, Leu353, Ile356,
Phe366, Leu368, Phe370,
Tyr377, and Val380 constitute a hydrophobic
core enclosed by the packing of the two orthogonal
sheets, and the
C-terminal amphipathic
helix packs with the apolar side toward the
sandwich. This hydrophobic core is characteristic of the
PTB/pleckstrin homology fold and contributes to its stability (33). The
predicted PTB domain of talin lacks the long insertion between the
1 and
2 strands observed in the PTB
domains of Shc (34), X11 (35), and Numb (36) and structurally is closer
to the PTB domain of insulin receptor substrate-1 (IRS-1) (37) (Fig.
2D). C-
atoms of residues in the core of the domain
superimpose with a root mean square deviation of 1.1 Å on the IRS-1
PTB domain structure. The PTB domain of IRS-1 binds ligands containing
phosphorylated tyrosine in the NPXY motif; interaction with
the phosphate group involves basic residues in the
4-
5 and
6-
7 loops. The PTB domain of talin does not contain basic residues in the equivalent
phosphate-binding loops. Thus, talin appears to lack the structural
requirements to recognize the phosphorylated form of NPXY
motifs. Therefore, the talin F3 subdomain binds integrin
tails,
activates integrins, and is predicted to be a PTB-like domain.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 7.
The talin F3 subdomain adopts a PTB-like
fold. A, ribbon representation of the homology model
for the F3 subdomain of talin; B, comparison of the F3
subdomain of talin (gray) with the PTB domain of IRS-1
(blue). Structures were aligned by superimposition of the
sheets. C- atoms of residues in the core of the subdomain
superimpose with a root mean square deviation of 1.1 Å. The ligand
recognition site in IRS-1 is formed by the 5 strand, the
4- 5 and
6- 7 loops, and the 1
helix. The figure was generated with MOLSCRIPT (47) and RENDER
(48).
|
|
Activation of Integrins Is Not a General Property of
3 Tail-binding Proteins or PTB Domains--
Cellular
expression of the
3 tail-binding talin F3
subdomain leads to integrin activation. This is not a general effect of
3 tail-binding proteins because talin F2, which also
binds the
3 tail, does not result in activation.
However, talin F2 binds
3 with a lower affinity than
talin F3. Therefore, we tested whether expression of higher affinity
3 tail-binding proteins resulted in activation of
IIb
3. The non-receptor tyrosine kinase
Syk binds to the
3 tail via an N-terminal fragment
containing the tandem SH2 (Src homology)
domains (Syk-(1-330)). This fragment binds to the
3
tail with an ~5-fold higher affinity (Kd = 24 nM) than the talin F3 subdomain (20). When we transfected cells with either full-length Syk or its N-terminal integrin-binding fragment (Syk-(1-330)), there was no change in integrin activation (Fig. 8A). Expression of the
transfected proteins was verified by Western blotting (Fig.
8C). Furthermore, because talin F3 is predicted to adopt a
PTB-like fold, we also tested whether expression of other PTB domains
resulted in integrin activation. Expression of the PTB
domain-containing proteins Numb (22) and Dok (21) and the isolated Dok
PTB domain did not significantly alter activation (Fig. 8B).
Hence, activation of
IIb
3 is neither a
general property of
3 tail-binding proteins nor of PTB
domains.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 8.
Activation of
IIb 3
is not a general property of 3
tail-binding proteins or of PTB domains. A, the effect
of expression of the 3 tail-binding protein Syk and the
integrin-binding fragment of Syk (Syk-(1-330)) on
IIb 3 activation was assessed as described
in the legend to Fig. 1. Results are expressed as percentage change in
activation index (mean ± S.E., n = 6). *,
p < 0.003. B, the effect of expression of
the PTB domain-containing proteins Numb and Dok and the isolated
Myc-tagged Dok PTB domain on IIb 3
activation was assessed as described above. Results are expressed as
percentage change in activation index (mean ± S.E.,
n = 6). *, p < 0.003. C, the expression of recombinant proteins in transfected CHO
cells was examined by Western blotting of cell lysates (7 µg) with
antibodies to Syk, Numb, Dok, or talin or to the Myc or hemagglutinin
epitope tag.
|
|
 |
DISCUSSION |
Alteration of integrin binding affinity in response to
intracellular signals (activation) is an important control mechanism for several integrin functions. Here, we report that a predicted PTB-like 96-amino acid subdomain of the talin FERM domain contains a
major integrin-binding site and activates integrin
IIb
3. PTB domains often recognize peptide
sequences containing NPXY motifs (38). Mutations within an
NPX(Y/F) sequence that is conserved in most integrin
cytoplasmic domains (31) inhibit talin interaction (5, 19, 39) and
integrin activation (3, 32). The conservation of the NPXY
motif, its role in talin binding, and its importance for integrin
activation suggest that activation by the PTB-like domain of talin is a
general property of talin-binding integrins and may require the
presence of a
turn formed by the NPXY motif.
The talin head domain is predicted to contain a PTB-like subdomain
within a putative FERM domain. FERM domains are found in a wide range
of proteins, and the degree of sequence identity between FERM domains
is often low (12). However, whereas the band 4.1 FERM domain exhibits
only 30% sequence identity and 50% similarity to the moesin and
radixin FERM domains, it is structurally very similar (root mean square
deviation C-
superposition of <2.0 Å) (15). The presence of a FERM
domain within talin has been proposed on the basis of primary sequence
alignments performed using several different programs (11-13, 16), and
comparison of the talin FERM domain with moesin or radixin reveals only
slightly lower levels of identity and similarity (23% identity and
46% similarity, respectively) than seen for the band 4.1 moesin/radixin comparisons. Pearson et al. (17) identified
six buried FERM residues that are highly conserved in FERM domains.
Five of these six residues are identical in talin, whereas the one
non-identical residue is a valine in place of a conserved glycine (Fig.
2). Together, these data suggest that the FERM fold is conserved in talin. FERM domains are composed of three subdomains (F1, F2, and F3),
and the F3 subdomains adopt a PTB-like fold (14-17). Modeling the
putative talin F3 subdomain by homology to the moesin structure indicates that the resulting fold has good structure packing quality and is similar to the IRS-1 PTB domain.
Loss-of-function mutations in the F3 module of known FERM domains are
predicted to be within the hydrophobic core of the protein and are
therefore likely to disrupt folding (15). Furthermore, known mutations
that disrupt PTB domain-ligand interactions do not fall within residues
conserved in talin (35-37). Thus, the identification of
surface-exposed residues in talin that are involved in binding to
integrins will require a structural analysis of the complex of the
talin PTB domain with an integrin
tail. In this study, we have
identified a 96-residue module of talin that binds and activates
integrin
IIb
3, whereas the previous
minimal integrin-activating fragment of talin was a 1071-amino acid
fragment of undefined structure. The structure and dynamics of the
3 cytoplasmic domain have been analyzed by NMR
spectroscopy of model protein mimics of the
3 tail (40).
The identification of the F3 subdomain as the fragment responsible for
activation will enable an NMR analysis of a protein-protein interaction
involved in integrin activation.
Our data suggest that the interaction of integrin
cytoplasmic
domains with talin resembles the binding of a PTB domain to a peptide
ligand in several ways. PTB domain-binding sequences, including
NPXY motifs, form
turns when bound to a PTB domain (38).
Consistent with such an interaction, the integrin
3
NPXY motif has the propensity to form a
turn (40), and
this propensity is lost as a result of mutations of the NPXY
motif that block both talin binding and integrin activation. Additional
PTB domain-ligand interactions are provided by the amino acid sequence
N-terminal to the
turn of the recognition motif (38). Consistent
with such an interaction, minimal talin-binding peptides contain the conserved first NPXY motif of integrin
1A
along with the preceding five amino acids (10, 39), providing
additional similarities between the peptide binding properties of talin
and authentic PTB domains. The integrin
3 tail does not
adopt a stable
turn conformation in solution (40). However, its
propensity to form a turn and its binding to the PTB-like F3 subdomain
of talin suggest that a stable turn will be present when talin binds to
integrins. We report here that the talin PTB-like F3 subdomain
activates integrins, whereas certain other
tail-binding proteins do
not. Furthermore, mutations that disfavor formation of a stable
turn block activation (3, 40). Hence, the integrin
tail-talin interaction bears many of the characteristics of PTB domain-ligand interactions, and the ability of the talin PTB-like F3 subdomain to
activate integrins may require a stable
turn at the conserved NPX(Y/F) motif.
This study demonstrates NPXY-dependent ligand
binding to the PTB-like FERM subdomain. Previous structural analyses
have suggested that NPXY-dependent interactions
of FERM domains could occur (17); however, this study represents the
first experimental documentation of this principle (16). There are now
261 proteins in the non-redundant data base predicted to contain FERM
domains (13). Thus, our studies may suggest a more general model for
other FERM domain interactions. They may also suggest a facile means
for identification of potential binding partners for FERM domains by
the presence of
turn-forming NPXY and related (38) sequences.
PTB domains were initially characterized as domains that bind to
phosphorylated tyrosines in the context of NPXY motifs (38). However, their binding is often independent of phosphotyrosine (36, 41,
42). The binding of talin or its PTB-like F3 subdomain to the integrin
tail does not require tyrosine phosphorylation of the integrin
tail because the bacterially expressed tail used in our binding assays
was not phosphorylated. Indeed, tyrosine phosphorylation of the
1A NPXY motifs may inhibit talin binding (10). Furthermore, in our model of the talin PTB subdomain, basic donor
groups that would coordinate the phosphate moiety are absent,
suggesting that binding of the phosphorylated NPXY motif is
energetically disfavored. Integrins are closely associated with talin
at focal adhesions, stable attachments formed in relatively non-migratory cells. Tyrosine phosphorylation of the
tail leads to
displacement of the integrin from these talin-rich structures (43).
tail tyrosine phosphorylation is also involved in
integrin-dependent cell migration and induces binding of
the PTB domain-containing protein Shc (44, 45). Hence, the tyrosine
phosphorylation state of the integrin
tail may determine which PTB
domain-containing
tail-interacting proteins associate with the
integrin. These phosphorylation-regulated changes in PTB domain binding
specificity may then be a molecular toggle switch that designates
migration or stable focal adhesion formation in response to
integrin-dependent adhesion.
 |
FOOTNOTES |
*
This work was supported by Grants HL-48728, HL-30915,
and AR-27214 from the National Institutes of Health, and by the Susan G. Komen Breast Cancer Foundation, and the American Heart Association. This is Publication 13988-VB from the Scripps Research Institute.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Dept. of Cell
Biology, Scripps Research Inst., CVN/Rm. 231, 10550 N. Torrey Pines Rd., La Jolla, CA 92037. Tel.: 858-784-7124; Fax: 858-784-7343; E-mail:
ginsberg@scripps.edu.
Published, JBC Papers in Press, April 3, 2002, DOI 10.1074/jbc.M111996200
 |
ABBREVIATIONS |
The abbreviations used are:
PTB, phosphotyrosine-binding;
GST, glutathione S-transferase;
SPR, surface plasmon resonance;
FACS, fluorescence-activated cell
sorter;
CHO, Chinese hamster ovary;
IRS-1, insulin receptor
substrate-1.
 |
REFERENCES |
| 1.
|
Hughes, P. E.,
and Pfaff, M.
(1998)
Trends Cell Biol.
8,
359-364[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Felding-Habermann, B.,
O'Toole, T. E.,
Smith, J. W.,
Fransvea, E.,
Ruggeri, Z. M.,
Ginsberg, M. H.,
Hughes, P. E.,
Pampori, N.,
Shattil, S. J.,
Saven, A.,
and Mueller, B. M.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
1853-1858[Abstract/Free Full Text]
|
| 3.
|
O'Toole, T. E.,
Ylanne, J.,
and Culley, B. M.
(1995)
J. Biol. Chem.
270,
8553-8558[Abstract/Free Full Text]
|
| 4.
|
Critchley, D. R.
(2000)
Curr. Opin. Cell Biol.
12,
133-139[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Calderwood, D. A.,
Zent, R.,
Grant, R.,
Rees, D. J.,
Hynes, R. O.,
and Ginsberg, M. H.
(1999)
J. Biol. Chem.
274,
28071-28074[Abstract/Free Full Text]
|
| 6.
|
Yan, B.,
Calderwood, D. A.,
Yaspan, B.,
and Ginsberg, M. H.
(2001)
J. Biol. Chem.
276,
28164-28170[Abstract/Free Full Text]
|
| 7.
|
Patil, S.,
Jedsadayanmata, A.,
Wencel-Drake, J. J.,
Wang, W.,
Knezevic, I.,
and Lam, S. C.-T.
(1999)
J. Biol. Chem.
274,
28575-28583[Abstract/Free Full Text]
|
| 8.
|
Martel, V.,
Racaud-Sultan, C.,
Dupe, S.,
Marie, C.,
Paulhe, F.,
Galmiche, A.,
Block, M. R.,
and Albiges-Rizo, C.
(2001)
J. Biol. Chem.
276,
21217-21227[Abstract/Free Full Text]
|
| 9.
|
Beckerle, M. C.
(1990)
Cell Regul.
1,
227-236[Medline]
[Order article via Infotrieve]
|
| 10.
|
Tapley, P.,
Horwitz, A.,
Buck, C. A.,
Duggan, K.,
and Rohrschneider, L.
(1989)
Oncogene
4,
325-333[Medline]
[Order article via Infotrieve]
|
| 11.
|
Rees, D. J.,
Ades, S. E.,
Singer, S. J.,
and Hynes, R. O.
(1990)
Nature
347,
685-689[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Girault, J. A.,
Labesse, G.,
Mornon, J. P.,
and Callebaut, I.
(1999)
Trends Biochem. Sci.
24,
54-57[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Schultz, J.,
Milpetz, F.,
Bork, P.,
and Ponting, C. P.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
5857-5864[Abstract/Free Full Text]
|
| 14.
|
Han, B. G.,
Nunomura, W.,
Takakuwa, Y.,
Mohandas, N.,
and Jap, B. K.
(2000)
Nat. Struct. Biol.
7,
871-875[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Edwards, S. D.,
and Keep, N. H.
(2001)
Biochemistry
40,
7061-7068[Medline]
[Order article via Infotrieve]
|
| 16.
|
Hamada, K.,
Shimizu, T.,
Matsui, T.,
Tsukita, S.,
and Hakoshima, T.
(2000)
EMBO J.
19,
4449-4462[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Pearson, M. A.,
Reczek, D.,
Bretscher, A.,
and Karplus, P. A.
(2000)
Cell
101,
259-270[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
LaFlamme, S. E.,
Thomas, L. A.,
Yamada, S. S.,
and Yamada, K. M.
(1994)
J. Cell Biol.
126,
1287-1298[Abstract/Free Full Text]
|
| 19.
|
Pfaff, M.,
Liu, S.,
Erle, D. J.,
and Ginsberg, M. H.
(1998)
J. Biol. Chem.
273,
6104-6109[Abstract/Free Full Text]
|
| 20.
|
Woodside, D. G.,
Oberley, T. D.,
Leng, L.,
Wilsbacher, J. L.,
Miranti, C. K.,
Brugge, J. S.,
Shattil, S. J.,
and Ginsberg, M. H.
(2001)
Curr. Biol.
11,
1799-1804[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Noguchi, T.,
Matozaki, T.,
Inagaki, K.,
Tsuda, M.,
Fukunaga, K.,
Kitamura, Y.,
Kitamura, T.,
Shii, K.,
Yamanashi, Y.,
and Kasuga, M.
(1999)
EMBO J.
18,
1748-1760[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Dho, S. E.,
French, M. B.,
Woods, S. A.,
and McGlade, C. J.
(1999)
J. Biol. Chem.
274,
33097-33104[Abstract/Free Full Text]
|
| 23.
|
Schuck, P.
(1997)
Annu. Rev. Biophys. Biomol. Struct.
26,
541-566[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Karlsson, R.,
Michaelsson, A.,
and Mattsson, L.
(1991)
J. Immunol. Methods
145,
229-240[CrossRef][Medline]
|